MedMira Inc V.MIR

Alternate Symbol(s): MMIRF

Technology Scientific & Technical Instruments

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.

TSXV:MIR - Post by User

MedMira Inc

Bullboard Posts

Comment by bobismydadon Sep 26, 2020 11:36pm

189 Views

Post# 31626117

RE:QUITE OBVIOUS EITHER A SABOTAGE OR A BIG GAME

not tests---we neded vaccines--mir is out of the race--stock says so

sic;;

AstraZeneca, which will supply up to 20 million doses of its viral vector vaccine candidate AZD1222.
Sanofi and GlaxoSmithKline, which will supply up to 72 million of doses of their protein subunit vaccine candidate.
Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate Ad26.COV2.S.
Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate NVX-CoV2373.
Pfizer, which will supply a minimum of 20 million doses of its mRNA vaccine candidate, BNT162. The government is negotiating with the company to expand the agreement to include options for obtaining additional doses.
Moderna, which will supply up to 56 million dosez